MRTX — Mirati Therapeutics Share Price
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.36 | ||
| Price to Tang. Book | 4.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 108 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -77.08% | ||
| Return on Equity | -69.95% | ||
| Operating Margin | -2002.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.93 | 3.33 | 13.4 | 72.09 | 12.44 | 61.72 | 178.98 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Directors
- Faheem Hasnain CHM
- Charles Baum PRE (63)
- David Meek CEO (58)
- Vickie Reed CFO
- James Christensen EVP (51)
- Benjamin Hickey EVP (46)
- Bruce Carter IND (78)
- Julie Cherrington IND (63)
- Aaron Davis IND (42)
- Henry Fuchs IND (63)
- Craig Johnson IND (59)
- Maya Martinez-Davis IND (50)
- Shalini Sharp IND (45)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 29th, 2013
- Public Since
- July 12th, 2013
- No. of Shareholders
- 12
- No. of Employees
- 587
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 70,147,706
- Address
- 3545 Cray Court, SAN DIEGO, 92121
- Web
- https://www.mirati.com/
- Phone
- +1 8583323410
- Auditors
- Ernst & Young LLP
Upcoming Events for MRTX
Q1 2024 Mirati Therapeutics Inc Earnings Release
Mirati Therapeutics Inc Annual Shareholders Meeting
Similar to MRTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Mirati Therapeutics share price?
As of Today at 18:14 UTC, shares in Mirati Therapeutics are trading at $58.80. This share price information is delayed by 15 minutes.
How has the Mirati Therapeutics share price performed this year?
Shares in Mirati Therapeutics last closed at $58.80 and the price had moved by +36.81% over the past 365 days. In terms of relative price strength the Mirati Therapeutics share price has outperformed the S&P500 Index by +12.29% over the past year.
What are the analyst and broker recommendations for Mirati Therapeutics?
The overall consensus recommendation for Mirati Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Mirati Therapeutics dividend yield?
Mirati Therapeutics does not currently pay a dividend.
Does Mirati Therapeutics pay a dividend?
Mirati Therapeutics does not currently pay a dividend.
When does Mirati Therapeutics next pay dividends?
Mirati Therapeutics does not currently pay a dividend.
How do I buy Mirati Therapeutics shares?
To buy shares in Mirati Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mirati Therapeutics?
As of the previous close price of $58.80, shares in Mirati Therapeutics had a market capitalisation of $4.12bn.
Where are Mirati Therapeutics shares listed?
Here are the trading details for Mirati Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MRTX
What kind of share is Mirati Therapeutics?
Based on an overall assessment of its quality, value and momentum Mirati Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mirati Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Mirati Therapeutics is $61.20. That is 4.08% above the last closing price of $58.80.
Analysts covering Mirati Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$11.10 for the next financial year.
Find out moreWhat is the trend in the Mirati Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mirati Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +76.73%.
As of the last closing price of $58.80, shares in Mirati Therapeutics were trading +29.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mirati Therapeutics PE Ratio?
The Mirati Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $58.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mirati Therapeutics?
Mirati Therapeutics' management team is headed by:
- Faheem Hasnain - CHM
- Charles Baum - PRE
- David Meek - CEO
- Vickie Reed - CFO
- James Christensen - EVP
- Benjamin Hickey - EVP
- Bruce Carter - IND
- Julie Cherrington - IND
- Aaron Davis - IND
- Henry Fuchs - IND
- Craig Johnson - IND
- Maya Martinez-Davis - IND
- Shalini Sharp - IND